---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-012231"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:12:11.054340+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics prioritizes tau/GBA1/SOD1-ALS pipeline, posts Q2 net loss of $19.1M

## Summary
- Q2 collaboration revenue $0.7M (down from $1.4M YoY); net loss $19.1M vs $30.1M in Q2 2021.
- Prioritized pipeline: tau antibody for Alzheimer's, GBA1 gene therapy for Parkinson's, SOD1 gene silencing for ALS.
- Identified receptor for TRACER AAV capsid; AAV9-derived capsid shows 50-60x better brain transduction vs AAV9.
- Catherine J. Mackey, Ph.D. (ex-Pfizer) appointed to Board of Directors, effective Aug 15, 2022.
- Cash $148.1M expected to fund operations into 2024; Pfizer option decision by Oct 2022, Novartis by Mar 2023.

## SEC filing metadata
- accession: 0001558370-22-012231
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837022012231/0001558370-22-012231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837022012231/vygr-20220804x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-012231
- JSON: https://secwatch.observer/filing/0001558370-22-012231.json
- Plain text: https://secwatch.observer/filing/0001558370-22-012231.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.